PENSACOLA, FL, USA, Sep 30, 2024/ Farcast, a pioneer and leader in human tumor microdynamics research, is extending its tumor microenvironment technology platform to incorporate peripheral markers from patient blood samples. With the addition of the new TruBlood extension, Farcast will elucidate both physiological and pathological processes of cancer response without the need for samples from tissue biopsies or surgeries. This approach has significant potential for clinical applications as it is minimally invasive while also increasing sensitivity and specificity in the biosignatures that Farcast develops.

Tissue derived biosignatures will continue to remain the cornerstone of Farcast’s platform, but these have limitations in continuous monitoring of patient response due to the invasive sampling method. A unique approach of coupling tumor microenvironment based core signals with peripheral signals obtained from blood samples will achieve more clinically suitable systems.

“Our work goes well beyond the current technologies involving circulating tumor cells and cell free tumor DNA. The mission is to overcome the challenge of accurate tumor response prediction in this field now with ways which are even more clinically powerful. Such tools will not only guide initial personalized treatment selection and drug development but will also be a source for longitudinal response metrics to guide treatment strategy over longer periods,” said Mohit Malhotra CEO of Farcast Biosciences.

Initial research has confirmed the feasibility of extending the existing platform driven perturbation signals to peripheral blood derived signals. Farcast anticipates launching the TruBlood extension in 2025 and expects the liquid biopsy based biosignatures to be able to guide both oncologists as well as oncology therapeutics developers in getting a more accurate reading of early and sustained response to any cancer therapy.